Evidence map›Paper›PMID 34009515›Full record

ArticleJournal of molecular histology2021

Silencing of Nek2 suppresses the proliferation, migration and invasion and induces apoptosis of breast cancer cells by regulating ERK/MAPK signaling.

Zeyu Xing, Menglu Zhang, Xin Wang, Jiaqi Liu, Gang Liu, Kexin Feng, Xiang Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular histology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Role of NEK2 in tumorigenesis and tumor progression.Trends in molecular medicine · 2025
    Review
  7. The NIMA-related kinase family and cancer.Frontiers in oncology · 2025
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zeyu Xing *Department Breast Cancer, Cancer Hospital, National Cancer Center/National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, PanJiaYuan NanLi, ChaoYang District, Beijing, 100022, China.
Menglu Zhang *Department Breast Cancer, Cancer Hospital, National Cancer Center/National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, PanJiaYuan NanLi, ChaoYang District, Beijing, 100022, China.
Xin WangDepartment Breast Cancer, Cancer Hospital, National Cancer Center/National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, PanJiaYuan NanLi, ChaoYang District, Beijing, 100022, China.
Jiaqi LiuDepartment Breast Cancer, Cancer Hospital, National Cancer Center/National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, PanJiaYuan NanLi, ChaoYang District, Beijing, 100022, China.
Gang LiuDepartment Breast Cancer, Cancer Hospital, National Cancer Center/National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, PanJiaYuan NanLi, ChaoYang District, Beijing, 100022, China.
Kexin FengDepartment Breast Cancer, Cancer Hospital, National Cancer Center/National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, PanJiaYuan NanLi, ChaoYang District, Beijing, 100022, China.
Xiang WangDepartment Breast Cancer, Cancer Hospital, National Cancer Center/National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, PanJiaYuan NanLi, ChaoYang District, Beijing, 100022, China. wangxiang_xwangx@163.com.
Chinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

Fundamental Research Funds for the Central Universities 3332020026
6 · The paper itself

Abstract

Breast cancer is a frequent cancer among women. The current study investigated the biological functions of Nek2 in breast cancer and its possible mechanism. The mRNA expression of Nek2 in breast epithelial cells and eight breast cancer cell lines was detected by qRT-PCR. Silencing Nek2 was transfected into MDA-MB-231 and MCF7 cells to examine its roles in the viability, migration, invasion, cell colony, apoptosis and cell cycle of the breast cancer cells by performing CCK-8, wound scratch, Transwell, clone formation and flow cytometry assays, respectively. The expressions of related genes were detected using qRT-PCR and Western blot. MAPK pathway agonist IGF (insulin-like growth factor-1) was added into MDA-MB-231 and MCF7 cells and then cell viability was examined. Nek2 expression was frequently up-regulated in breast cancer cell lines, and silencing Nek2 significantly inhibited the viability, cell migration, invasion and clone formation, promoted cell apoptosis of MDA-MB-231 and MCF7 cells, and arrested cell cycle in G0/G1 phase. Furthermore, knocking down Nek2 decreased the mRNA and protein expressions of Bcl-2, CyclinB1 and CyclinD1, and increased Bax and p27 expressions. Moreover, knocking down Nek2 inhibited the phosphorylation of ERK and p38, and almost completely reversed the expression of p-ERK increased by IGF, but Nek2 knockdown had no obvious effect on p-p38. The inhibitory effect of Nek2 silencing on the cell viability was mainly realized by the inhibition of ERK/MAPK signaling. Nek2 plays an important role in the regulation of the progression of breast cancer in vitro probably through regulating the ERK/MAPK signaling.

Indexed as

Gene SilencingApoptosisBlotting, WesternBreast NeoplasmsCell CountCell CycleCell Line, TumorCell MovementCell ProliferationCell SurvivalFemaleFlow CytometryGene Expression Regulation, NeoplasticHumansMAP Kinase Signaling SystemNeoplasm InvasivenessNEK2 protein, humanNIMA-Related KinasesBiological functionBreast cancerERK/MAPK signalingNek2

Identifiers

PMID34009515
OpenAlexW3162837984

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.